Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter(University of Tübingen), Claus Garbe(University of Tübingen), Rudolf Herbst(Helios Klinikum Erfurt), Ulrike Keim, Cord Sunderkötter(MSB Medical School Berlin), Peter Martus(University of Tübingen), Carola Berking(Universitätsklinikum Erlangen), Cornelia Mauch(University Hospital Cologne), Thomas Vogt(University Dermatology), Martin Kaatz(SRH Wald-Klinikum Gera), Norbert H. Brockmeyer(Ruhr University Bochum), Werner Hohenberger(Universitätsklinikum Erlangen), K.W. Schulte(Heinrich Heine University Düsseldorf), Percy Lehmann(Helios Universitätsklinikum Wuppertal), Jan‐Christoph Simon(Leipzig University), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Jens Ulrich, Wolfgang Gehring(Städtisches Klinikum Karlsruhe)
Cited by 704
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Evaluating the public health impact of health promotion interventions: the RE-AIM framework.
|American Journal of Public Health|1999|7.2k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k